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EVALUATION OF AUTOREACTIVITY IN VH4-34-CONTAINING ANTIBODIES FROM HUMAN B-1 VS
B-2 CELLS
Michelle E. Ray, M.S.
Western Michigan University, 2020
B-1 cells are a unique population of lymphocytes, with distinct phenotypic and functional
characteristics in comparison to conventional B-2 cells. B-1 cells are thought to be more closely
related to the innate immune system than the adaptive, and B-1 cells constitutively secrete
antibody that is recognized as broadly reactive with low levels of autoreactivity. The antibody
heavy chain segment, VH4-34, is overutilized by the human B-1 cell population. VH4-34
antibodies are associated with autoreactivity, although not all VH4-34 antibodies are
autoreactive. The primary objective of this study was to determine whether autoreactive forms
of VH4-34 antibodies are localized only to the B-1 cell population, or whether VH4-34 antibodies
are autoreactive wherever they are found. We obtained cells from healthy human donors, sorted
cells individually, PCR amplified antibodies, and then cloned and expressed the antibodies. The
monoclonal antibodies were then tested against a series of autoantigens to determine if B-1 or
B-2 cells produced more autoreactive VH4-34-containing antibodies. Results suggested that B-1
cells did produce more autoreactive/polyreactive VH4-34-containing antibodies than memory B2 cells, though the population observed was small and more samples are required in order to
provide statistical significance.
NIH Grant R01 AI029690 “Aberrant signaling in B1 cells”

ACKNOWLEDGMENTS
I would like to thank Dr. Tom Rothstein for taking a chance on a guinea pig and in turn
providing me with one of the best opportunities I have ever had to learn and grow as a scientist
and a person, as well as providing an immense level of continued support throughout my time in
his lab. I would like to thank Dr. Robert Eversole for serving on my committee as well as providing
my spark and interest in the realm of immunology and pathology as strongly as he did. I would
also like to thank Dr. John Spitsbergen setting up the opportunity for me to do work with Dr.
Rothstein and for providing additional support through the years. I would like to thank both
Angela Brightwell and Alex Ludlow for being great mentors in one way or another, whether it be
helping to teach critical techniques, sorting cells for me, or simply helping me troubleshoot
tedious steps. I would like to thank many of the other members of the Center for Immunobiology
as well, for continued support, instrumentation guidance, and navigating the realms of
sequencing and flow cytometry that are well beyond my years. I would also like to thank Dr.
Nichol Holodick for taking the time on multiple occasions to sit down with me on a one-on-one
basis to sift through the massive amounts of genetic data I had obtained.
In addition to the professional help, I would like to thank my mother as I do not think I
could have done this without her. Every single time I faltered, she was there to help me with a
hug, kind words, or a surprise visit to encourage me to just keep moving forward. Thank you for
everything Momma. I love you.
Michelle E. Ray
ii

TABLE OF CONTENTS

ACKNOWLEDGMENTS ................................................................................................................. ii
LIST OF TABLES ........................................................................................................................... vi
LIST OF FIGURES ........................................................................................................................ vii
INTRODUCTION ........................................................................................................................... 1
B-1 Cells ........................................................................................................................... 1
Antibodies........................................................................................................................ 4
The Human Antibody Repertoire..................................................................................... 6
Autoreactivity .................................................................................................................. 7
VH4-34 ........................................................................................................................... 10
METHODS .................................................................................................................................. 12
B Cell Isolation ............................................................................................................... 12
B Cell Enrichment .......................................................................................................... 13
Cell Staining ................................................................................................................... 13
Single Cell Sorting .......................................................................................................... 14
cDNA Synthesis .............................................................................................................. 15
Single Cell RT-PCR and Gene Amplification ................................................................... 16
Vector Cloning ............................................................................................................... 20
iii

Table of Contents – Continued

Transfection ................................................................................................................... 22
Concentrating the Samples ........................................................................................... 23
Sample Purification........................................................................................................ 24
Determining Reactivity and Polyreactivity .................................................................... 24
CDR3 Analysis ................................................................................................................ 25
Determining Hydrophobicity ......................................................................................... 25
Statistical Analysis ......................................................................................................... 25
RESULTS ..................................................................................................................................... 26
Primer Optimization ...................................................................................................... 26
Serum Optimization....................................................................................................... 28
VH4-34 Utilization ......................................................................................................... 29
Sequencing, CDR-H3, and Mutations............................................................................. 30
Hydrophobicity .............................................................................................................. 34
Reactivity Summary ....................................................................................................... 35
DISCUSSION ............................................................................................................................... 40
VH4-34 Utilization ......................................................................................................... 40
Sequencing, CDR-H3, and Mutations............................................................................. 40
Hydrophobicity .............................................................................................................. 42
Reactivity ....................................................................................................................... 43
Future Directions ........................................................................................................... 45
iv

Table of Contents – Continued

CONCLUSION ............................................................................................................................. 47
BIBLIOGRAPHY ........................................................................................................................... 49

v

LIST OF TABLES

1. Primer Sequences .......................................................................................................... 19
2. VDJ and CDR3 characteristics of cloned antibodies determined by Sanger
sequencing..................................................................................................................... 31
3. Summary of antibody binding strength against all antigens tested .............................. 39
4. Antigens coating the ELISA plates ................................................................................. 44

vi

LIST OF FIGURES

1. Novel gating strategy designed and implemented by our lab to separate
human B-1 cells, memory B cells, and mature (naïve) B cells from
whole blood ................................................................................................................... 15
2. Example of an Igκ sequence alignment to restriction enzyme-specific
primer ............................................................................................................................ 18
3. Comparison of original primer method to modified single-primer
method .......................................................................................................................... 27
4. The results of one transfection time trial and serum optimization with a
single sample transfected multiple times with different
concentrations of FBS in the transfection media........................................................... 29
5. The utilization of VH4-34 in memory and B-1 samples ................................................. 30
6. Length of CDR-H3 region for cloned antibodies ............................................................ 33
7. Nucleotide mutations for variable gene of all cloned antibodies.................................. 34
8. Hydrophobicity of all cloned antibodies with emphasis on which cell
type originally produced the antibodies........................................................................ 35
9. Anti-dsDNA and Anti-Insulin ELISA results..................................................................... 36
10. Anti-cardiolipin ELISA results ......................................................................................... 37
11. Anti-nuclear Antibodies (ANA) ELISA results ................................................................. 37
12. ANA ELISA results (cont.) ............................................................................................... 38

vii

Introduction
B-1 Cells
B-1 cells are a distinct subpopulation of B lymphocytes that behave differently from, and
appear phenotypically different than, conventional B-2 cells. They are unique from B-2 cells in
that they more closely resemble the innate immune system than the adaptive. They do not need
foreign antigen for antibody stimulation and thus spontaneously secrete natural antibody,
predominantly IgM, which provides a baseline level of protection before a pathogen even enters
the body (Montecino-Rodriguez & Dorshkind, 2012) (Rothstein et al., 2013) (Baumgarth, 2016).

B-1 cell antibodies (Abs) are known for their broad specificity to many antigens found
naturally in the body (Montecino-Rodriguez & Dorshkind, 2012). B-1 cells also act as
housekeepers in that they clean up cellular debris and molecular toxins from the break-down of
cells, thereby providing a homeostatic balance to the body. They can also help defend against
microbial pathogens and foreign invaders prior to the body’s adaptive immune response, as these
B-1 cells are present prior to birth and can secrete antibodies, coined “natural antibodies”,
spontaneously and very early in development (Rothstein & Quach, 2015) (Rodriguez-Zhurbenko
et al., 2019).

Often times mice or other non-human organisms are used as models to study biological
systems, however, observations in other species do not always correlate directly to Homo
sapiens. In the murine system, B-1 cells are known to be derived from a separate progenitor than
B-2 cells, resulting in a separate lineage (Rothstein et al., 2013). Also, in the murine system, the
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key identifying phenotypic marker for the B-1 population is CD5, a marker that is typically present
on T cells (there are actually two subpopulations of B-1 cells in the murine system: B-1a that are
CD5+ and B-1b that are CD5-). Mice also have germ line-like antibodies that arise from B-1 cells
with little somatic mutation or N-addition (Rothstein & Quach, 2015).

Not all of these things can be said for the human system. There have been a few theories
as to whether the B-1 cell population arises separate from the B-2 cell population via different
lineages or if they share a lineage and one cell population is likely converted to another through
maturation. Although there has been a separate progenitor found in the mouse, recent results in
the last few years have suggested that in humans, these populations of cells share a progenitor
as human Lin-CD34+CD38lo stem cells reconstituted both cell populations (Quách et al., 2016).
Yet, this area still remains a highly debated and controversial subject.

The CD5 surface marker used to be the essential in distinguishing B-1 cells from other
subpopulations until it was noted that human CD5+ cells were found in human chronic
lymphocytic leukemia (CLL), as well as representing 15-30% of circulating B cells and up to nearly
75% of umbilical cord blood B cells in healthy individuals, which was remarkably high in
comparison to the number of cells that were CD5+ in mice (Rothstein et al., 2013) (Rothstein &
Quach, 2015). In addition to an excess number of CD5+ cells present, CD5- B cells were also
secreting autoreactive antibodies much like their CD5+ counterparts, further indicating that the
presence of the marker was not indicative of a separate cell population (Rothstein & Quach,
2015). Furthermore, CD5 was also found on human B-2 cell populations (transitional, pre-naive,
2

and activated B cells) indicating that it was not a key identifying marker for human B-1 cell
populations alone (Griffin et al., 2011).

It was also discovered that human CD5+ B cells differ in additional ways from the murine
system, in that human CD5+ B cells have higher levels of somatic hypermutation (SHM) and
junctional diversity. The increased levels of junctional diversity could be due to the presence of
terminal deoxynucleotidyl transferase (TdT) in humans that is missing in mice in earlier stages of
hematopoietic cell development (Mrczek et al., 2014). CD5 was clearly not a good marker to use
to distinguish B-1 cells from conventional B-2 cells in the human B cell repertoire.

The inability to easily identify the B-1 cell population phenotypically in humans led to
questions regarding the existence in humans of this population. However, phenotype is only one
way to define a cell type. By using a set of distinctive functional features of mouse B-1 cells
(spontaneous secretion of IgM, T cell stimulation, and chronic intracellular signaling), a series of
experiments were performed to “reverse engineer” the phenotypical profile of the human B-1
cell population which helped serve as the template for which cells were classified as B-1 cells for
the single cell sort in this work (Rothstein et al., 2013).

Based upon the results of these experiments, B-1 cells are phenotypically described as
CD20+CD27+CD38lowCD43+ which differs from the memory (CD27+CD43-) and naïve (CD27-CD43-)
profiles. The B-1 cell profile is also different from the plasma cell or plasmablast profile as human
B-1 cells express CD20 which is lost during differentiation to the plasmablast stage, and human
3

B-1 cells do not express CD138 which is acquired by these differentiated plasma cells. Also
excluded from the B-1 cell profile are CD19+CD20+CD27+CD38+ “pre-plasmablast” cells that share
a similarity to plasmablasts in CD27 and CD38 expression, to eradicate the possible confusion
between the B-1 cell and plasmablast/pre-plasmablast populations (refer to figure 1 for flow
cytometry gating strategy for single cell sorting) (Griffin et al., 2011) (Rothstein & Quach, 2015) .

Antibodies
Antibodies are the proteins that are secreted from B cells to protect the body from foreign
invaders or pathogens. Typically, these proteins arise once B cells have been previously exposed
to an antigen of some sort, whether it be bacterial (i.e. Streptococcus pneumoniae) or viral (i.e.
influenza), but in the case of B-1 cells, these proteins can be produced spontaneously without
prior exposure to foreign antigens.

Each antibody has a basic “Y” shape in which two identical heavy chains (HC) (composed
of variable (V), diversity (D), and joining (J) segments) and two identical light chains (LC)
(composed of variable (V) and joining (J) segments) are joined. Each one of these chains has a
constant and a variable region. The variable regions of the two chains come together to form the
antigen binding site that determines the specificity of the antibody. This antigen binding site
consists of 6 hypervariable loops (complementarity determining regions – CDRs), 3 of which come
from each of the heavy and light chains (Almagro et al., 1997) (Foreman et al., 2007).
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At the center of this antigen binding site is the CDR3 region, in which the specific CDR3
region from the HC (CDR-H3) is the most variable component of the antigen binding region as it
is the product of V(D)J recombination and N-region addition (Mroczek et al., 2014). It plays a
central role in specifying antigen binding. This characteristic region has been well studied and
many distinctive patterns have been elucidated to help predict binding patterns of specific
antibodies. Beyond specifying recognition of foreign antigens, some of these CDR3 patterns are
associated with autoreactivity. An example includes identifying that arginine is often found in
CDR-H3 regions of dsDNA autoantibodies (antibodies that attack self-antigens) (Silva-Sanchez et
al., 2015).

Other features of CDR3 regions have been characterized in that the average CDR3 length
differs in disease (Foreman et al., 2007). While the CDR3 length alone cannot predict if the
antibody will be autoreactive, longer CDR3 regions have been associated with autoreactive or
polyreactive antibodies (average length consists of approximately 15.5 ± 3.2 amino acids) (Shi et
al., 2014). In addition to length, the presence of positively charged amino acids in the CDR-H3
region has also been associated with autoreactive or polyreactive antibodies (Wardemann et al.,
2003) (Huang et al., 2018). It is also key to note that as the cells mature or are exposed to antigen,
they typically produce antibodies that have decreased or shortened CDR3 lengths that increase
in charge (Silva-Sanchez et al., 2015) (DeKosky et al., 2016). This would lead one to believe, by
previous observations, that antibodies produced from memory cells or other B-2 cells, are more
likely to have shorter CDR3s than antibodies that are produced from B-1 cells that have not been
exposed to antigens previously.
5

The Human Antibody Repertoire
The human antibody repertoire is diverse, and for good reason. The body is pelted with
all sorts of foreign matter, be it viruses or bacteria, that the system needs to be able to defend
itself against. In addition to simply being able to protect us from the these threats, the body
needs to be able to adapt to these new exposures when they happen, as there is no way our body
would be able to predict every single antigen that exists that we could be exposed to before it
happens.

There are a few main mechanisms by which the repertoire continues to expand. The first
is through V(D)J recombination that occurs in early stages of B cell development, through the
random rejoining of different gene segments in the V-D-J regions (Wardemann & Nussenzweig,
2007). Due to the many possible combinations in which these segments could join together, the
body has the ability to form an antibody that could react with virtually anything (Andris et al.,
1995). On the other hand, that also means that with all of these possible combinations, it is highly
likely that a great deal of the antibodies that are produced are also autoreactive. Many of them
actually recognize nuclear self-antigens and are polyreactive at this stage (Tiller et al., 2007).

The second mechanism that expands the body’s antibody repertoire is through sequence
variation via random, non-template-encoded nucleotide addition (N-addition) at the V-D and DJ junctions typically of the heavy chain. Terminal deoxynucleotidyl transferase (TdT) can add up
to 20 nucleotides to the single-stranded ends of the coding DNA significantly altering the genetic
sequence of the produced antibody (Kumar, Abbas, & Aster, 2015).
6

Another mechanism that contributes to the body’s ever-growing antibody repertoire is
somatic hypermutation (SHM) when mature B cells are responding to antigen challenge. These
random point mutations during SHM create polyreactive and self-reactive antibodies as well
(Tiller et al., 2007). While antibodies are theoretically only supposed to bind to one antigen,
according to the lock and key theory, in reality, some antibodies react to many antigens resulting
in polyreactivity (Casali & Notkins, 1989). Polyreactive antibodies have the ability to recognize
several epitopes, although normally with decreased affinity compared to standard nonpolyreactive antibodies. In addition to causing polyreactivity, SHM can also cause an increase in
affinity of autoreactive antibodies (Foreman et al., 2007).

Autoreactivity
Autoreactivity, the break in tolerance in a body’s immune system, has been implicated in
several immune diseases and disorders, such as systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA). This occurs when B cells that recognize self-epitopes produce
antibodies against antigens located naturally in the body. These cells typically produce antibodies
at a high rate and have high affinities for these self-epitopes (Corsiero et al., 2014; Richardson et
al., 2013; Malkiel et al., 2016). These antibodies are often directed against other cell surface
markers or against other naturally occurring antigens present in the body. In the cases of systemic
lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome (SS), and scleroderma,
systemic autoantibodies are present throughout the system that react to DNA, RNA, histone,
ribonucleoprotein particles, antinuclear antibodies (ANAs) and other antigens (Stollar, 1991).
7

It is important to note that autoreactive antibodies are present in low levels in healthy
serum (Stollar, 1991). The mere presence of autoreactive antibodies does not result in clinical
significance. It is the high abundance and the type of antibody that determines association with
clinical illness. The production of the pathogenic antibody alone may not be that significant for
the disease to even develop but may in turn provide an indication of underlying disease, not
necessarily be the cause of it (Foreman et al., 2007).

The body must have a means to control the number of autoreactive cells that are present
in the body. While it is unknown for certain the percentage of cells that are eradicated through
B cell maturation, observations indicate that a large number of the self-reactive B cells are lost
through the process. It is estimated that 55-75% of all antibodies emerging in the bone marrow
are autoreactive which can be attributed to the failure of the body’s natural checkpoints to
eliminate or anergize the cells, or to the random N-additions or SHM in the CDR-H3 region that
allow autoreactive antibodies to be reintroduced into the system (Wardemann et al., 2003).

To prevent the escape of autoreactive antibodies into the system, the body has 3 natural
mechanisms that account for the silencing of most autoreactive B cells during development:
Receptor editing, clonal deletion, and anergy.

Receptor editing includes a secondary rearrangement of light chains with heavy chains in
an attempt to alter the antigen-binding site’s specificity therefore preventing the persistence of
8

autoreactive receptors (Foreman et al., 2007). This process contributes to the exclusion of the
majority of autoreactive clones (20%-50%)( Wardemann & Nussenzweig, 2007) (Hoffman et al.,
2016)

Clonal deletion is only a secondary line of defense for the cells that are not successfully
rearranged from their autoreactive ways during receptor editing. If a B cell receptor recognizes
self-antigen with a strong enough signal, the cell triggers apoptosis (negative selection) to
prevent the cell from producing antibodies against itself (Wardemann & Nussenzweig, 2007)
(Hoffman et al., 2016).

Anergy is the state of hypo-responsiveness where the cells typically survive for a
shortened duration of 1-5 days (Hoffman, Lakkis, & Chalasani, 2016). The cells become
unresponsive to antigen stimulation so that no antibody production can occur, and they are often
prone to apoptosis as they are essentially useless cells. Their numbers are then rapidly lost from
the cell repertoire (Wardemann & Nussenzweig, 2007).

Most often when autoantibodies are present in an autoimmune disease they are
generally IgG (Foreman et al., 2007). They are not highly cross-reactive, react with high affinity,
and are encoded by genes that have undergone mutations from the germline through V(D)J
recombination or somatic hypermutation, all of which is typically quite different from natural
antibodies (Stollar, 1991), at least as delineated in the mouse system. Patients that have these
autoimmune diseases often frequently produce many autoreactive antibodies that react to
9

various antigens, although not all of the antibodies produced may have the same specificity or
are equally as pathogenic (Foreman et al., 2007).

VH4-34
VH4-34 is a gene that codes for a variable region of the heavy chains of immunoglobulins.
The VH4-34-derived immunoglobulins constitute less than 1% of total serum immunoglobulins in
humans but can increase in response to infections (Pugh-Bernard et al., 2001)(Cambridge et al.,
2014). While it is known that VH4-34-derived antibodies have a higher chance of being
autoreactive than those that are derived from other variable heavy chain genes, it is unknown
which types of cells predominantly produce these autoreactive antibodies and in particular, if
they are segregated into a single cell subpopulation, such as the B-1 cell subpopulation. (Milner
et al., 2005).

The development of systemic lupus erythematosus (SLE) has been studied greatly and has
been largely attributed to the autoreactivity of antibodies produced in the body. VH4-34-derived
antibodies have been specifically implicated in this development of SLE as a high proportion of
the autoreactive antibodies are VH4-34 (Mockridge et al., 1998) (Milner et al., 2005). VH4-34derived antibodies are also known to be autoreactive towards the I/i of red blood cells (RBCs)
that are an antigenic target of pathogenic autoantibodies in cold-agglutinin (CA) disease. The
many additional targets of VH4-34-containing Abs include bacterial LPS, chromatin, cardiolipin,
and DNA (Alcéna et al.,2013) (Cambridge et al., 2014) (Sanz, 2014).
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Recent results have shown that the VH4-34 gene is overrepresented in the normal adult
B-1 cell antibody repertoire as compared to other B cell populations, where it is present in lesser
numbers (Rodriguez-Zhurbenko, et al., 2019). Considering that VH4-34 is known to encode
autoreactive antibody, and that B-1 cells are thought to generate autoantibodies, the question is
raised as to whether VH4-34 antibodies are autoreactive in every cell population in which they
appear, or whether they are autoreactive only in the B-1 cell population. We believe that B-1 cells
are responsible for producing more VH4-34-containing autoreactive antibodies than other B cell
populations.

It is for these reasons that we focused on identifying which cells produced the VH4-34derived autoreactive antibodies. We know that not all VH4-34-containing antibodies are
autoreactive, and we know that naturally occurring autoreactive antibodies are present in
healthy human serum, but we do not know if significantly more autoreactive VH4-34 antibodies
come from B-1 cells than from B-2 cells. We obtained cells from healthy human donors, sorted
the cells individually (figure 1), and cloned and expressed the antibodies. The monoclonal
antibodies were then tested against a series of antigens to determine if B-1 or B-2 cells produced
more autoreactive VH4-34-containing antibodies. We were able to identify that B-1 cells
produced more antibodies that were autoreactive than B-2 antibodies (although not significantly
so).

11

Methods
Acquisition of blood and single cells was performed by other members of the lab. Their
procedures are outlined in the sections entitled “B Cell Isolation” through “Single Cell Sorting.”

B Cell Isolation
Human blood samples were collected at Western Michigan University Homer Stryker
M.D. School of Medicine from healthy donors and delivered to the lab where the samples were
processed immediately upon arrival to prevent damage to the lymphocytes in the sample. Human
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors using standard
density gradient separation in Lymphocyte Separation Medium (Corning, Ref 25-072-CV).

Fresh blood was placed in heparin-coated collection tubes (Green Cap BD VacutainerTM,
BD 367874) at 10 mL/vial. These tubes were spun at 1,800 RPM for 10 minutes at room
temperature. The majority of the plasma was removed from the sample and the first Buffy Coat
(thin white layer between the red blood cell and plasma fractions) was collected and placed into
a 50 mL conical tube. Equal volume of standard wash medium (RPMI with penicilin/streptomycin,
and L-glutamine) was added to the Buffy Coat fraction then underlayed with an equal volume of
Lymphocyte Separation Medium. The sample was centrifuged at 2,000 RPM for 20 minutes (with
the break off) at room temperature. The second Buffy Coat was transferred to a new 50 mL
conical tube and centrifuged for 10 minutes at 1,800 RPM at room temperature. The supernatant
was aspirated from the sample and the pellet was resuspended in 50 mL of standard wash
medium. The sample was counted and immediately followed by B cell enrichment or frozen for
12

future additional processing.

B Cell Enrichment
B cells were enriched by magnetic bead selection using the EasySep Human CD19 Positive
Selection Kit according to the manufacturer’s instructions.

Cell Staining
CD19 enriched B lymphocytes were washed with 3 mL of sort/wash/staining buffer (PBS,
0.5% BSA, and 2 mM EDTA). The cells were centrifuged and the pellet was resuspended in 2.5 µL
of normal mouse serum per 1 x 106 cells, to block Fc receptors on the cell surface and the cells
were incubated for 5 minutes on ice.

The antibody staining cocktail was freshly prepared using optimized antibody
concentrations. Components of the staining cocktail include the following anti-human mouse
monoclonal antibodies: anti-CD3-BV605 (Clone HIT3a; BD Biosciences 564712), anti-CD4-BV605
(Clone SK3; BD Biosciences 565998), anti-CD19-APC-Alexa700 (Clone J3-119; Beckman Coulter
A78837), anti-CD20-Pacific Blue (Clone B9E9; Beckman Coulter A74777), anti-CD27-PE (Clone MT271; BD Biosciences 557330), anti CD38-PC5.5 (Clone LS198-4-3; Beckman Coulter A70205),
anti-CD43-FITC (Clone DFT1; Beckman Coulter IM3264U), and Aqua LIVE/DEAD™ viability stain.

The cocktail was then added to the concentrated cell suspension and incubated on ice for
30 minutes, protected from light. The cells were washed with sorting buffer and separated via
13

centrifugation for 10 minutes at 1,200 RPM at 4°C. The cell pellet was resuspended with sorting
buffer and the wash repeated. Washed cells were resuspended at a final concentration of 10 x
106 cells/mL. Stained cells were acquired on the BD INFLUX cell sorter. Gates were created
around populations of cells based on the antibody staining profile of the sample according to the
gating strategy shown below in figure 1.

Single Cell Sorting
B-1 and Memory cells were sorted 1 cell per well into 96 well plates that contained lysis
buffer (IgePAL, RNAsa Out, Carrier RNA, DTT, and 5x First Strand/ RT III Buffer). The plates were
sealed and then flash-frozen on dry ice and stored at -80oC until the samples were ready to be
processed.

Figure 1 illustrates the gating strategy that was used during one of the single cell sorts to
obtain a single donor’s healthy B cells. Each consecutive plot indicates a more restricted set of
criteria to identify single cells of interest (B-1 and Memory).
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Figure 1. Novel gating strategy designed and implemented by our lab to separate human B-1 cells, memory B
cells, and mature (naïve) B cells from whole blood. The trigger pulse width and forward scatter allows for
separation of singlets from doublets. Side scatter vs Aqua LIVE/DEAD dye is used to obtain only living cells.
CD3/4/7 are used as a dump channel for T cells vs CD19+ B cells. CD19+CD20+ are next sorted to exclude
plasmablasts that are CD19+CD20-. CD19+CD20+CD27hiCD38hi (preplasmablasts) are next excluded. Among
CD19+CD20+CD38mod B cells, naïve, memory and B-1 cell populations were single cell sorted based upon
expression of CD27 and CD43, as indicated.

cDNA Synthesis
Once cells were sorted into the 96 well plates, a master mix of random hexamers, 10mM
dNTP mix, and SuperScript III RT was added to the cell lysates to generate cDNA. The plates were
placed in an Applied Biosystems ProFlex PCR System thermocycler with the following run time
protocol: 42°C for 10 mins, 25°C for 10 mins, 50°C for 10 mins, 94°C for 5 mins, and held at 4°C.
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Single Cell RT-PCR and Gene Amplification
There are two rounds of semi-nested PCR required for each chain amplified (IgG, IgM, Igκ
and Igλ) (Tiller et al., 2008). For the first-round of semi-nested PCR, a master mix of 10x PCR
buffer, 10 mM dNTP mix, HotStarTaq Plus, PCR grade water, 25 µM of chain-specific forward
primer(s), and 25 µM of chain-specific reverse primer(s) (table 1) was prepared on ice while the
cDNA was thawed on ice, if it was frozen. A volume of 23.75 µL of master mix was added to each
well of a new 96 well plate, on ice, and 1.25 µL of cDNA was then added to the plate. The plates
were immediately sealed and spun briefly at 1,200 rpm. The plate was then placed in the
thermocycler with the following run time protocol: 94°C for 5 mins followed by 50 cycles of 30
seconds at 94°C, 30 seconds at 57°C, and 55 seconds at 72°C, then followed by 7 minutes at 72°C
and held at 4°C.

For the second-round of semi-nested PCR, a master mix of 10x PCR buffer, 10 mM dNTP
mix, HotStarTaq Plus, PCR grade water, 12.5 µM of chain-specific forward primer(s), and 25 µM
of chain-specific reverse primer(s) (table 1) was prepared on ice while the first-round PCR
products were thawed on ice, if they were frozen. 23 µL of master mix was added to each well of
a new 96 well plate, on ice, and 2 µL of the first-round PCR products were then added to the
plate. The plates were immediately sealed and spun briefly at 1,200 rpm. The plate was then
placed in the thermocycler with the following run time protocol: 94°C for 5 mins followed by 50
cycles of 30 seconds at 94°C, 30 seconds at 57°C, and 45 seconds at 72°C, then followed by 7
minutes at 72°C and held at 4°C.
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To specifically examine VH4-34-containing antibodies, a specific VH4-34 primer was used
as a forward primer instead of the originally published 13-primer mix (Tiller et al., 2008), after
determining through a series of experiments that only using the one primer would not skew the
number of VH4-34 amplifications that occurred which in turn significantly streamlined the PCR
process greatly.

After second-round amplification of heavy chains, the plates were analyzed on the Qiagen
QIAxcell Advanced system using the QIAxcel DNA Screenig Kit (2400) cartridge to determine
which wells amplified. The wells that amplified were sequenced using the VH4-34 primer either
in house using our SeqStudio Sanger sequencer or sent to Genewiz to confirm the samples were
VH4-34.

Igκ amplification required an additional series of steps in order to add proper restriction
enzyme-specific cut sites during amplification. After the initial second-round of semi-nested PCR
with PanVK as the forward primer, the plates were analyzed on the QIAxcell to determine which
wells amplified. These samples were sequenced using the PanVK primer either in house using our
sequencer or sent to Genewiz.

Once sequencing information was obtained for Igκ, the sequences were aligned with the
restriction enzyme-specific primers using Serial Cloner software to determine the best primers
to use to reamplify the second-round of semi-nested PCR. When the best-aligned primers were
identified (figure 2), the second round of amplification was performed again using the newly
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identified forward and reverse primers. After amplification, samples were once again analyzed
on the QIAxcell to identify which samples amplified with the new primers.

Figure 2. Example of an Igκ sequence alignment to restriction enzyme-specific primer.
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Table 1. Primer Sequences
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Vector Cloning
The amplified samples were purified using the Takara PCR/Gel purification kit and double
digested with their respective restriction enzymes for 2 hours at 37°C with a 20-minute
inactivation at 65°C. Heavy chains were digested with Agel-HF and Sall-HF, Igκ was digested with
Agel-HF and BsiWi-HF, and Igλ was digested with Agel-HF and Xhol.

In addition to the samples having to be digested, the plasmid backbones that they were
inserted into had to be digested as well using the same chain-specific restriction enzymes. Each
chain also had specific backbones or vectors that were used: heavy chain (HC) was AbVec2.0IGHG1, Igκ was AbVec1.1-IGKC, Igλ was AbVec1.1-IGLC2-Xhol.

Digested samples and plasmids were run on 1% agarose gels made with 1x TAE at 120 mV
for approximately 40 minutes or until the samples were about 0.5” away from the edge of the
gel. The gel was then stained for 20 mins with 20 mL of 1x GelRed in a dark location and then
photographed on a ChemiDoc. Once the gel had been photographed, the purified bands near 400
base pairs were excised and purified using the Takara PCR/Gel purification kit. The OD A260/280 nm
was measured to obtain the DNA concentration of the samples via the BioTek Epoch2 microplate
reader.

Purified digested samples and vectors were ligated using the Takara ligation system. 20
ng of vector and 16 ng of insert were incubated together at 65°C for 2 minutes to disrupt the
insert-insert and plasmid-plasmid interactions. The solution was cooled to 4°C on ice and then
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Takara solution was added. After, the temperature was raised and the samples were then ligated
for 2 hours at 16°C.

OneShot competent E. coli cells were transformed with ligated samples via heat shock. 2
µL of ligation mix was added to 20 µL of E. coli cells and left on ice for 30 minutes. The samples
were heat shocked at 42°C for 30 seconds using a water bath and then immediately placed on
ice again for at least 5 minutes. 180 µL of SOC medium was added to the samples and they were
horizontally shaken at 37°C in a shaker/incubator at 225 rpm for exactly 1 hour. 200 µL of sample
was spread on warmed agar plates that contained ampicillin to ensure only transformed cells
grew and the plates were placed, inverted, overnight in an incubator at 37°C.

A negative control with an empty cut plasmid backbone was used, as well as a positive
control with uncut plasmid. A single colony per sample was used to inoculate 25 mL of Terrific
Broth with ampicillin and placed overnight in a horizontal shaker incubator at 37°C in order to
expand the culture.

A glycerol stock was made of each sample consisting of 500 µL of 50% glycerol with 500
µL of bacterial culture. After the glycerol stock was made, the bacterial pellet was harvested from
the culture by centrifuging the sample at 6,000 x g for 15 minutes at 4°C. The plasmid DNA was
recovered from the bacterial pellet using the Qiagen MIDI prep kit. The OD A260/280 nm was
measured to obtain the DNA concentration of the samples via the Epoch2.
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The purified plasmid DNA was sent for sequencing to ensure the correct orientation of
the insert in the vector and to ensure the presence of VH4-34 in the heavy chain plasmids by
using the SP6 universal primer from Genewiz.

Transfection
Human embryonic kidney cell (HEK293T) cultures were prepared in advance to
transfections. Cells were grown in complete DMEM (Dulbecco's Modified Eagle Medium) 1x (with
phenol red) with 4.5 g/L glucose, L-glutamine, and sodium pyruvate (Corning, Ref. 10-013-CV)
supplemented with 10% heat inactivated and filtered Fetal Bovine Serum (FBS)

and 1x

penicillin/streptomycin in 10 cm Falcon Tissue Culture-Treated Dishes.

The day before a transfection, the cells were split, and the media changed accordingly.
Transfection media consisted of phenol red and antibiotic free DMEM supplemented with 4%
FBS to ensure efficient purification of the collected supernatant via FPLC. Cells were plated at
100,000 cells/cm2 (approximately 1.5 x 106 cells/mL) to ensure the cells were not overconfluent
the following day.

On the day of transfection, cells were observed under a microscope to ensure proper
growth and health before transfection. Cells were co-transfected with IgH (heavy chain) and IgL
(light chain) chain-specific plasmids using Lipofectamine 3000 following the manufacturer’s
protocols for optimal transfection efficiency. Transfected plates were carefully placed in the CO2
at 5% incubator at 37°C.
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The first collection of supernatant occurred two days post transfection (day 3 of the
procedure) and collection continued every 2 days until either the cells died or 11 days post
transfection transpired. The supernatant was carefully removed from the plates using a syringe
and filtered through a 0.22-micron filter to ensure any cells that were possibly removed from the
plate with the supernatant did not contaminate the collected supernatant. Cells that were
potentially in the supernatant were removed to protect the antibodies from potential degrading
enzymes that would be released after cell death. The transfection media was carefully replaced
without detaching the cells from the plates and the plates were placed back into the CO2
incubator between each collection. No wash step was performed between collections to increase
survival rates of cells by preventing accidental detachment from cell culture plates during the
process. A small amount of supernatant, approximately 2 mL, remained on the plate between
each collection day to prevent negative reactions from cells to entirely new media as well as
preventing additional cells from being removed during collections. The collected supernatant
from each day was pooled into one 50 mL falcon tube per sample and kept at 4°C until all
collections were completed.

Concentrating the Samples
Dialysis tubing with a 10kDa MWCO was used to concentrate the collected supernatant
samples. Supernatant from all collection days for a single sample was added to the dialysis tubing
which was covered with polyethylene glycol (PEG) 20,000. The samples were left in the PEG until
there was approximately 10 mL of sample remaining in the tubing. The sample was removed from
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the tubing using a needle and syringe and stored in the syringe sealed with parafilm at 4°C until
ready to be purified (no longer than 2 days).

Sample Purification
Samples were purified via FPLC and a Bio Rad Bio-Scale Mini UNOsphere SUPrA Cartridge
protein A column with 0.02 M sodium phosphate pH 7.5 as the wash buffer and 0.1 M glycine pH
2.5 as the elution buffer. Purified samples were collected in test tubes containing 100 µL of 1.0
M TRIS pH 8.8 with a fractionator assembly connected to the FPLC. The fractions containing the
purified antibodies were placed in a Thermo Scientific Slide-A-Lyzer Dialysis Cassette G2 (Prod#
87735) and put in a container filled with excess 1x PBS overnight at 4°C while being stirred to
exchange the buffer the antibodies are stored in. The final samples were transferred to a Pierce
Protein Concentrator (ref 88517) and spun in a centrifuge until the sample volume is
approximately 1 mL. The OD A280 nm was measured to obtain the concentration of the antibody
via the Epoch2.

Determining Reactivity and Polyreactivity
The ELISA kits from ORGENTEC Diagnostika GmbH (anti-dsDNA, ORG 604; anti-insulin ORG
520) and Abnova (anti-cardiolipin, KA0941; ANA Profile, KA1079) were used for basic qualitative
binding of the cloned and purified monoclonal antibodies to determine autoreactivity to dsDNA,
insulin, cardiolipin, and additional ANA proteins. The manufacturer’s instructions were followed
initially and additional adjustments in concentrations of sample added to the pre-coated plates
were made to optimize the procedure for purified antibodies compared to serum or plasma.
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Absorbances were collected via Epoch2 and data analysis was performed using GraphPad Prism
version 8 using the recommended 4-Parameter-Fit (4PL) with lin-log coordinates for the
ORGENTEC anti-dsDNA and anti-insulin kits and Excel was used for the simple calculations
required for the Abnova anti-cardiolipin and ANA Profile kits.

CDR3 Analysis
CDR-H3 analysis was performed using IMGT/HighV-QUEST and NCBI IgGBlast to gather
information from genetic sequences. Gathered information was then analyzed using GraphPad
Prism version 8.

Determining Hydrophobicity
The hydrophobicity of the samples was determined in conjunction with materials
provided from Harry W. Schroeder Jr, MD and Andre M. Vale. Gathered information was then
analyzed using GraphPad Prism version 8.

Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 8. Levels of statistical
significance were determined via unpaired Mann-Whitney tests with the significance taken as p
≤ 0.05.
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Results
Primer Optimization
The original method for the heavy chain semi-nested PCR amplification required the use
of a 13-primer mixture that was designed to amplify all human VH segments. As we were only
interested in amplifying 1 particular gene segment, VH4-34, the original method was modified
slightly to include the use of a single VH4-34-specific forward primer during the second-round of
amplification instead of the 13-primer mix. By eliminating the use of multiple primers, multiple
days were eliminated from the workflow as the sequencing confirmation of amplified samples
was no longer required.

The alteration to the method was tested several times, in which many samples were
amplified using both the original and the modified protocol, and sequences were compared for
any variation to the results in amplification. After examining the sequences, it was noted that the
single VH4-34 primer method resulted in no false positive, nor false negative amplifications in
comparison to the original 13-primer mix method (figure 3).
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A

B

C

Figure 3. Comparison of original primer method to modified single-primer method. A) One row of IgM
amplification of B1 cells that utilized the multiple primer mix. B) Same row of IgM amplification of B1 cells but
using only VH4-34 primer as forward primer. C) Sequence alignment to VH4-34 confirming the identity of the
sample.
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Serum Optimization
The original protocol called for 10% serum in the transfection media which resulted in
very difficult working conditions once the collected supernatant was concentrated with dialysis
tubing/PEG and needed to be inserted into the FPLC for purification. In addition to this difficult
working situation, an optimized length of time in which supernatant containing antibodies should
be collected from the transfected cells had not been determined. These factors were evaluated
by varying the percentage of FBS supplemented (0%, 0.5%, 1%, 2%, 3%, and 4%) into the
transfection media and multiple samples were transfected, supernatants collected every two
days post transfection, and antibody levels monitored via ELISA.

FBS concentrations below 2% were lethal to the HEK293T cells and thus not recorded in
figure 4. As noted in this trial, samples with 4% of FBS in the transfection media produced the
most antibodies as determined by ELISA. The amount of antibody production after 2 weeks post
transfection significantly decreased to the point that little to no antibody was being produced
which led to the modification of the original protocol that called for 22 days of collection post
transfection to end after 12 days post transfection.
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Figure 4. The results of one transfection time trial and serum optimization with a single sample transfected
multiple times with different concentrations of FBS in the transfection media.

VH4-34 Utilization
An intermediate step to producing monoclonal antibodies is sending VH4-34 amplified
PCR products for sequencing for each of memory and B-1 samples. While not all of these samples
were cloned, sequencing information was still collected and analyzed. Figure 5 shows a clear
overutilization of VH4-34 in B-1 cells compared to memory cells.
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Figure 5. The utilization of VH4-34 in memory and B-1 samples.

Sequencing, CDR-H3, and Mutations
22 monoclonal antibodies were cloned from single cells, 12 originating from B-1 cells and
10 originating from B-2 memory cells. Genetic sequencing via Sanger sequencing was performed
to obtain information about their diversity and joining regions, however, no significant pattern
was able to be discerned from the information gathered. Regardless of the groupings, either via
isotypes of origin, cell of origin, D regions, or J regions, no critical information was gleamed about
their potential binding capabilities nor were any correlations made to their CDR-H3 regions (table
2).
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In addition to not being able to draw conclusions based upon the V(D)J information gained
from sequencing, no patterns were able to be recognized from the mutational analysis either as
the lengths of the CDR-H3 did not seem to be impacted by the number of nucleotide mutations
(table 2). The cell of origination or isotype of origination did not seem to be an influencing factor
on the length of the CDR-H3 nor the number of mutations either (table 2).

Table 2. VDJ and CDR3 characteristics of cloned antibodies determined by Sanger sequencing
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Table 2 – continued
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Figure 6. Length of CDR-H3 region for cloned antibodies.

33

Figure 7. Nucleotide mutations for variable gene of all cloned antibodies.

Hydrophobicity
While levels of mutation and the length of the CDR-H3 regions of the clones were not
significantly different between VH4-34-containing antibodies that originated from B-1 cells
compared to those that originated from conventional B-2 memory cells, the hydrophobicity did
show a difference and there was a level of significance between the two subpopulations. While
there does not seem to be a key indicative pattern between each sample’s hydrophobicity and
it’s CDR-H3 length, number of mutations, binding strength to any antigen tested, or original
antibody isotype, antibodies that came from B-1 cells do seem to be more positively charged
than those that originated from memory samples. It is interesting to note, as indicated in figure
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7, that the polyclonal B-1 cell antibody does not follow this trend, but actually appears to be
slightly negatively charged sharing the similar charge with two other B-1 samples (all charges
listed by sample in table 2) that do not share in the same type of binding patterns.

Figure 8. Hydrophobicity of all cloned antibodies with emphasis on which cell type originally produced the
antibodies. Note: the labeled sample is the positive binding, polyreactive antibody.

Reactivity Summary
To observe the potential autoreactivity/polyreactivity of VH4-34-containing antibodies
produced from B-1 and B-2 cells, we tested cloned and expressed antibodies for binding towards
dsDNA, insulin, cardiolipin, and several nuclear antigens. The presence of these potentially
autoreactive antibodies are implicated in several autoimmune disorders/diseases.
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B1_1_A12_IgG_D2 bound to every antigen tested in all ELISA assays (figures 9-12). Other
samples did show minor binding activity and were thus considered positive for low-level binding,
except for the dsDNA assay where 2 other B-1 samples (B1_2_A8_IgM_D2 and
B1_3_C11_IgG_D2) and a single memory sample (Mem_6_C12_IgG) (figure 9a) were considered
positive for moderate-level binding. However, the polyreactive B1_1_A12_IgG_D2 bound to
dsDNA strongly enough to be considered strongly autoreactive. Table 3 provides a summary of
the reactivity of all cloned antibodies.

A

B

dsDNA

Insulin

Figure 9. Anti-dsDNA and Anti-Insulin ELISA results. A) Anti-dsDNA; B) Anti-Insulin Note: the labeled sample is
the positive binding, polyreactive antibody.
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Cardiolipin

Figure 10. Anti-cardiolipin ELISA results. Note: the labeled sample is the positive binding, polyreactive
antibody.

A

Anti-RNP-70

B

Anti-RNP/Sm

Figure 11. Anti-nuclear Antibodies (ANA) ELISA results. A) Anti-RNP-70; B) Anti-RNP/Sm. Note: the labeled
sample is the positive binding, polyreactive antibody.
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C

Anti-Sm

D

Anti-SS-A

E

Anti-SS-B

F

Anti-ScI-70

H

Anti-Jo-1

G

Anti-Centromere B

Figure 12. ANA ELISA results (cont.); C) Anti-Sm; D) Anti-SS-A; E) Anti-SS-B; F) Anti-ScI-70; G) Anti-Centromere
B; H) Anti-Jo-1. Note: the labeled sample is the positive binding, polyreactive antibody.
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No binding or negative (-) strength of binding (IU/mL) index cutoff for all tests was determined by the internal standards of the assays
adjusted for antibody only testing; + indicates low level binding for samples above the mean; ++ for moderate level of binding above
the mean; +++ for samples demonstrating high or strong levels of binding above the mean.

Table 3. Summary of antibody binding strength against all antigens tested

Discussion
VH4-34 Utilization
Based on previous literature, we know that VH4-34 is over utilized in B-1 cells to
approximately 8% which I have also been able to replicate based off of my results (figure 5). This
previous literature also compared the VH4-34 usage in memory cells to approximately 2% (Quách
et al., 2016). While my numbers are a bit high, nearing 4%, there is still a clear distinction that
VH4-34 is overutilized B-1 cells compared to memory cells.

Sequencing, CDR-H3, and Mutations
Much of what is known about the CDR-H3 region in terms of pattern has been elucidated
from mice. However, it has been proven incredibly difficult to obtain comparative data from
human specimens as there is enhanced variability of the human repertoire, especially when
compared to the CDR-H3 region. This increased variability can be attributed to the greater
diversity of the germline sequence in the DH gene segments and an increase in N-additions
(Mroczek et al., 2014).

While some mice antibodies do have nucleotide additions (N-additions), the cells that
produce these additions, along with somatic hypermutation, are the more mature cells, such as
the conventional B-2 memory cells. Murine system B-1 cells are mainly germline-like and contain
little to no somatic hypermutation or N-additions. N-additions are often thought to be missing
from early B cell development in mice as the required enzyme terminal deoxynucleotidyl
transferase (TdT) is not present during that developmental period. TdT adds a random number
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of N-nucleotides to the end of the heavy chain during V(D)J recombination resulting in nontemplated nucleotide additions and a further variation away from the original germ-like template
(Wardemann & Nussenzweig, 2007) (Rothstein et al., 2013). This is quite different in the human
system, however, as TdT is present early in cell development indicating that human B-1 cells may
not be as germline-like as their murine counterparts (Pugh-Bernard et al., 2001).

Typically, with CDR-H3 there is a unique pattern in amino acid composition, length, and
charge distribution as B cells mature, even in the human system (Mroczek et al., 2014).
Stereotypically, length decreases and there is an increase in highly charged amino acids located
in the CDR3 loop, which would have led to the antibodies produced from the memory population
having a shorter CDR-H3 length with more highly charged amino acids. As memory cells leave the
bone marrow having completed their VDJ recombination and N-additions stages, the only way
for memory cells to alter their CDR-H3 regions is through somatic hypermutation (SHM) from
antigen exposure. However, there was no significant difference identified between the lengths
of the antibodies produced from the different subpopulations (figure 6) and there was no
significant difference observed between the amino acid composition of the CDR3 loops of the
antibodies produced from the different subpopulations (not pictured).

In addition to the length of the CDR-H3 region and the amino acid composition of the
CDR3 loop, the average number of mutations from the germline sequence of an antibody should
increase through maturation. As a cell develops and continues through the process of SHM, the
genetic variability of the antibody repertoire should continue to expand. What should have been
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observed was an increase in mutations from germline sequences for the memory samples
compared to the B-1 samples that have not been exposed to external antigens or gone through
somatic hypermutation. However, we observed no statistically significant difference between the
subpopulations in terms of which population had more total variable chain mutations than the
other (figure 7).

Hydrophobicity
The hydrophobicity of an antibody is determined by the amino acid composition near the
antigen binding site. Each amino acid plays an important role in determining the reactivity of the
antibody as well as determining the overall charge. Somatic hypermutation is a good example of
how each amino acid plays a key role in determining the antigenic binding capacity of the
antibody. As random point mutations occur due to antigen challenge, antibodies become more
diversified and the body’s repertoire expands (Wardemann & Nussenzweig, 2007). These random
point mutations can alter the amino acid composition of the antibody and therefore alter the
binding capability.

As mentioned before, generalized patterns in antibody structure and composition are
conserved evolutionarily through species, including hydrophobicity. Theoretically, memory cells,
or conventional B-2 cells that have been exposed to antigen, should have shorter CDR-H3 regions,
but they should also be composed of more positively charged amino acids. However, this was not
what was observed. The majority of the cloned memory antibodies had negative
hydrophobicity’s with only one being positively charged. The B-1 cells, however, did have a level
42

of significant difference in hydrophobicity compared to memory B cells. There were a few
samples that were near the lower negatives much like the lower memory samples, but the mean
hydrophobicity of the B-1 cell antibodies was higher at just about neutral in comparison to the
generally negative memory B cell antibodies. However, there were two B-1 antibodies that were
significantly more positive, above +0.5, that stood out. There was nothing that was easily able to
be identified that would indicate why these samples were so significantly different than the
remaining B-1 samples, or any of the memory samples, in terms of reactivity, CDR-H3 length,
mutations, or original antibody isotype.

Reactivity
Based on previous explanations, predicted observations included a significant increase of
reactivity of the B-1 antibodies compared to the memory antibodies. As the original B cells all
came from healthy donors, the B-2 cells should have all undergone check points as they matured
to ensure self-reactive cells either did not survive, or produce autoreactive antibodies, resulting
in a decrease in the number of cloned antibodies that should react to the self-antigens that
coated the plates in the ELISAs.

Each of the antigens that coated the different plates are known to be commonly
associated with autoreactivity in different autoimmune disorders/diseases, such as systemic
lupus erythematosus (SLE), scleroderma, Sjögren's Syndrome, mixed connective tissue disease,
and idiopathic inflammatory myopathies (table 4). (Stollar, 1991). Many of these antigens are
also specifically targeted in the human system when it is afflicted with SLE and these tests would
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provide a baseline level of autoreactivity produced by B-1 and B-2 antibodies which could be
judged against the typically elevated levels of autoreactive antibodies detected in SLE patients.

Table 4. Antigens coating the ELISA plates

While some believe that immunological autoreactivity predominantly occurs due to
antibodies that arise from conventional B-2 cells, that is not the picture that seems to be drawn
from the results of the different ELISA results. While 22 cloned antibodies, 12 from B-1 and 10
from memory, may not provide statistical significance, we can see that only 1 antibody sample,
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a B-1 sample, of 22 was considerably polyreactive. This B-1 antibody was originally IgG. We can
also see that only 1 memory sample that was originally IgG, of the 10 cloned, showed moderate
reactivity to any test, whereas 3 out of 12 B-1 samples (2 were IgG and 1 was IgM) had at least
minor reactivity to at least 1 test. Again, it does not provide statistical significance, but it does
hint in the direction that VH4-34-derived antibodies produced from B-1 cells may indeed be more
autoreactive in healthy donors than those that are derived from conventional B-2 cells.

Future Directions
We know that VH4-34 is overutilized in B-1 cells compared to other cell populations and
that it is often associated with autoreactivity and autoimmunity. We also know that B-1 cell
antibodies are known for being broadly reactive with low levels of autoreactivity. These
observations led us to further study VH4-34-containing antibodies and which B cell population
predominantly produced them. We sought to find out if significantly more B-1 cells produced
more autoreactive VH4-34 Abs than other B cell populations and if VH4-34-containing Abs were
only autoreactive when derived from B-1 cells.

We did observe that autoreactivity was mainly found in B-1 population, though the
population observed was small and requires more samples in order to provide statistical
significance. However, we also noticed that there seems to be no obvious correlations of
autoreactivity with the other antibody characteristics including D-usage, J-usage, CDR-H3 length,
hydrophobicity, isotype origination, mutational analysis, or specific CDR-H3 motif that could be
observed.
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Overall, more donors are required to obtain true statistical significance for these tests.
Some tests, such as the hydrophobicity and the obvious color change in the ELISAs, gave an idea
of whether or not memory samples or B-1 samples followed our basic ideas and hypothesis.
However, in order to further cement or ground our ideas on whether or not VH4-34-derived
antibodies that arise from B-1 cells are more autoreactive than those that arise from memory
cells, more samples are required. Once more samples are obtained, we can then seek to confirm
our initial finding that although there are VH4-34-containing antibodies in both the B-1 and B-2
cell populations, the autoreactive VH4-34-containing antibodies are only found in the B-1 cell
population.

In addition to obtaining more samples, testing additional subpopulations, such as the
naïve subpopulation, would give additional insight into whether or not autoreactive VH4-34
antibodies are segregated into B-1 or B-2 subpopulations. Once additional subpopulations and
more samples are tested to obtain a solid baseline for autoreactive antibodies in healthy donors,
testing can be expanded to SLE patients to identify differences between baseline autoreactivity
and diseased levels of VH4-34 autoreactivity in B-1, memory, and additional subpopulations.

Besides additional subpopulation testing, an additional immunofluorescence assay
utilizing HEp-2 cells could be performed to characterize the reactivity of the antibodies. This
indirect immunofluorescence assay (IIFA) is an important and well recognized diagnostic tool for
many autoimmune diseases (Damoiseaux et al., 2019). The assay is based on identifying the
varieties of antinuclear antibodies (ANAs) that are present in a sample based upon the staining
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pattern of the antibodies. Different staining patterns indicate antibodies reacting with different
antigens (dsDNA, nucleosomes, histones, Sm, RNPs, centromere, etc.). By identifying the staining
patterns, clinicians can rule out certain diseases as many of the diseases that have elevated levels
of ANAs have particular patterns, such as the homogenous staining pattern observed in SLE
samples where antibodies react with dsDNA, nucleosomes, and histones (Kumar, Abbas, & Aster,
2015, p. 220). The simple presence of ANAs (a large category of antibodies that are occur in
various autoimmune diseases) is not enough to classify antibodies as pathogenic or indicate what
disease they may or may not result in.

Conclusion
Identification of the human B-1 cell subpopulation is important for the study of
autoreactivity in people. The B-1 cell population has been studied extensively in mice, and for
various reasons, using mouse B-1 cells as a representative population does not accurately reflect
how human B-1 cells behave, function, and appear naturally in the system.

Throughout recent years, there have been many differing opinions to what human B-1
cells are and or whether human B-1 cells really exist. Yet, in recent years, the development of
phenotypic criteria that were defined by identifying human B-1 cells that displayed functions
similar to those of mouse B-1 cells has strengthened the case for the existence of B-1 cells. Now,
we are able to elucidate more clearly key information these cells may play on
autoimmunity/autoimmune disorders as well as other maladies in the human system.
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However, the classification of these cells is far from complete. Perhaps, with the better
characterization of human B-1 cells, and in turn their functions and their potential pathogenic
idiosyncrasies, we will be able to further contribute to the development of therapeutic advances
that could prevent the progression of autoimmune disorders or treat those that currently suffer
from symptoms (Griffin et al., 2011).
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